[{"orgOrder":0,"company":"Sanford Burnham Prebys Medical Discovery Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scientists Identify a New Drug Target for Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Sanford Burnham Prebys Medical Discovery Institute"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas, University of Pittsburgh Enter Research Collaboration for Dry Age-Related Macular Degeneration Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Synedgen","sponsor":"National Eye Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synedgen Receives Supplemental NEI Funding To Identify Lead Development Candidate for Ocular Mustard Gas Injury Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Synedgen"},{"orgOrder":0,"company":"SemaThera Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Roche","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"SemaThera Inc"},{"orgOrder":0,"company":"Mosaic Biosciences","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocular Therapeutix\u2122 and Mosaic Biosciences Ink Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Mosaic Biosciences"},{"orgOrder":0,"company":"Intergalactic Therapeutics","sponsor":"ATPGroup","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Intergalactic Therapeutics"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"SparingVision","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR\/Cas9 Technology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Intellia Therapeutics"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kriya Announces $270 Million Series C Financing to Advance Fully Integrated Gene Therapy Engine","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Kriya Therapeutics"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy to Enhance AAV Gene Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Codiak BioSciences"},{"orgOrder":0,"company":"Toolgen","sponsor":"mCureX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"SOUTH KOREA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Toolgen"},{"orgOrder":0,"company":"Avista Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,007.5 million","upfrontCash":"$7.5 million","newsHeadline":"Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Avista Therapeutics"},{"orgOrder":0,"company":"VivaVision","sponsor":"Everads Therapy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"VivaVision"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Under the terms of collaboration agreement, VivaVision and Everads will jointly conduct pre-clinical research activities, in order to identify lead candidates for future clinical development and commercialization.
The partnership aims to apply Avista’s single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology to develop intravitreal AAV capsids matching a capsid profile defined by Roche.
The two companies plan to conduct gene corrections in ocular tissues using mCureX's mRNA technology and ToolGen's TGT-101 & CRISPR/Cas9 gene-editing technology for the treatment of rare hereditary eye diseases.
Codiak’s proprietary engEx Platform is designed to enable the development of engineered exosome therapeutics for a wide spectrum of diseases and to manufacture them reproducibly and at scale to pharmaceutical standards.
Proceeds from this financing will support the advancement of Kriya’s pipeline and continued scaling of its engineering, manufacturing, and computational platforms. Kriya has established an ecosystem for delivering best-in-class technologies and medicines in gene therapy.
As part of this collaboration, Intellia will grant SparingVision exclusive rights to Intellia’s proprietary in vivo CRISPR/Cas9-based genome editing technology including SPVN50 for up to three ocular targets addressing diseases with significant unmet medical need.
Intergalactic’s non-viral gene therapy deploys two proprietary technologies: 1) C3DNA, covalently closed and circular DNA which relies on a cellfree manufacturing process; and 2) COMET, a clinically advanced, pulsed electric field focal gene therapy delivery system.
Under terms of the agreement, the collaboration between Ocular Therapeutix and Mosaic focuses on the discovery and development of novel complement inhibitors with extended duration of activity.
The partnership will focus on developing SemaThera’s promising new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases.
Synedgen has developed a new class of glycopolymers with the ability to suppress inflammation, reduce infection, and improve healing at mucosal surfaces. The additional funding provides resources to optimize down-selection to a lead molecule to advance into animal studies.
Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
